Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study ...
The gastroparesis market is poised for significant growth, driven by the emergence of novel therapeutic classes such as the Dopamine D2 receptor antagonist (GIMOTI). Meanwhile, novel therapies like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback